Germany has received nearly 900 applications for cannabis cultivation associations, but only just over half have been approved as clubs struggle with licensing, location rules, financial risk, and inconsistent enforcement. At the same time, medical cannabis patients face new reimbursement restrictions that could force tens of thousands to pay out of pocket, switch treatments, or challenge the reforms in court.
The German cannabis landscape continues to change constantly. Local authorities have already received 896 applications to establish cannabis cultivation associations for adults. Of those, only 455 have been approved, according to data compiled by the Federal Association of German Cannabis Growers (BCAv) and shared by International CBC.
In other words, just over half of the applications submitted have successfully made it through the authorization process. The figure confirms the growing interest in this model, but it also highlights the gap between forming an association, securing a license, and actually beginning legal production.
Cultivation associations—often called cannabis social clubs—began applying for permits on July 1, 2024, three months after the first phase of Germany’s Cannabis Act took effect. Unlike a dispensary or retail store, these are nonprofit organizations that collectively grow cannabis to supply their adult members.
The law allows each association to have up to 500 members, who must be at least 18 and have lived in Germany for the previous six months. Club membership must last for a minimum of three months, a measure designed to prevent so-called “cannabis tourism.”
Cannabis Is Legal, but There Are No Stores—and No On-Site Consumption
The German model has several distinctive features. Clubs may grow and distribute cannabis to their members, but they may not sell it to the public, mail it, or operate as commercial businesses. Consumption is also not permitted on the club’s premises.
Each member may receive up to 25 grams per day and 50 grams per month. For members aged 18 to 21, the monthly limit is reduced to 30 grams, and the product’s THC content cannot exceed 10%. Cannabis must be handed over in person, after verifying both age and membership.
Associations must also monitor inventories, document cultivation and distribution, ensure product traceability, and periodically report their stock levels to the authorities. Cannabis must be handed over in neutral packaging, accompanied by information on its weight, strain, harvest date, average THC and CBD levels, and potential risks associated with use.
But before reaching that point, interested groups must go through an authorization process that can include everything from background checks to plans for security, youth protection, prevention, storage, and access control.
Finding a suitable location is no easy task either. The law stipulates that facilities must be located at least 200 meters away from schools, youth centers, and playgrounds. Additionally, land or buildings designated for growing cannot be part of a private residence.
It’s worth noting that the way these rules are applied varies across Germany’s federal states. The BCAv itself has pointed out that some clubs face difficulties obtaining building and use permits, even when they plan to operate in industrial zones. The lack of uniform criteria and differing interpretations of the regulations can delay or outright block projects that had already moved forward with investments and planning.
Eight Obstacles to a Model That Aims to Displace the Illicit Market
The difficulties are not limited to official statistics. A study by researchers at Aarhus University, published in the International Journal of Drug Policy, analyzed how administrative burdens are hindering the early stages of German associations.
The researchers combined survey responses from 32 associations with seven semi-structured interviews with their representatives. Based on this work, they identified eight major challenges:
- the need for an extremely committed individual to drive the project forward
- financial risks
- finding suitable facilities
- obtaining a license
- unclear legal terminology
- the 200-meter rule
- the ban on consumption within the club
- social stigma.
The first point is particularly revealing. Although the clubs are supposed to be nonprofit organizations rather than commercial entities, their creation often depends on one person willing to invest time, money, and energy for months on end with no guarantee that a permit will be granted. Initial costs may include rent, legal counsel, equipment, security systems, and building renovations long before the first harvest.
According to the researchers, these barriers could limit the associations’ ability to meet three of the reform’s stated objectives: reducing risks, protecting young people, and displacing part of the illicit market.
If only groups with sufficient capital, legal knowledge, and the persistence needed to navigate the bureaucracy manage to access the system, the model runs the risk of remaining too limited to provide a meaningful legal alternative.
Germany’s Public Health System Faces Obstacles of Its Own
Furthermore, the tightening of regulations is not limited to adult-use associations. Recently, Germany’s public health insurance system stopped reimbursing the cost of treatment with medical cannabis flower. The measure took effect without a transition period, even for patients whose treatment had already been approved and was underway.
The change does not prevent doctors from continuing to prescribe flowers or patients from purchasing them at pharmacies. What it does eliminate is coverage under statutory health insurance, so those who wish to continue treatment will have to pay for it out of pocket, switch therapies, or try to qualify for an exception.
The reform also tightens reimbursement rules for cannabis extracts, dronabinol, and nabilone. To begin one of these treatments, patients will, in most cases, have to undergo a six-month trial with an approved finished cannabis-based medicinal product. The problem, according to doctors and industry organizations, is that these products are approved for very specific indications and are not suitable substitutes for many of the conditions currently treated with cannabis.
The Federal Association of Cannabinoid Pharmaceutical Companies (BPC) estimates that around 65,000 patients with established treatments could be affected. The organizations also warn that there is no approved inhalable finished medicinal product in Germany that can directly replace cannabis flower for patients who need rapid effects, including some receiving palliative care.
With the measure set to take effect, several groups began seeking to overturn it through the courts. The Association for Cannabis as Medicine (ACM) announced that it will file a constitutional complaint with the Federal Constitutional Court, arguing that the legislation is based on the mistaken assumption that all cannabis-derived medications are interchangeable. The German Hemp Association (DHV) stated that it will support the initiative.
The measure does not directly affect clubs, which operate outside the medical system and cannot provide cannabis on prescription or replace pharmaceutical care. However, it helps illustrate Germany’s current regulatory landscape: while the country is authorizing community associations for adults, it is imposing new economic and administrative barriers on medical patients.
In both cases, a similar tension arises. The law recognizes legal avenues for access, but the bureaucracy, costs, and requirements necessary to use them can still place them out of reach for part of the population.
Germany has created a legal, community-based pathway to cannabis access, but turning that possibility on paper into fully operational clubs is proving far more difficult than simply submitting an application. At the same time, the loss of coverage for medical cannabis flower shows that Germany’s shift toward broader access is neither linear nor equally beneficial to everyone who uses it.
